nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Dysarthria—Doxorubicin—muscle cancer	0.00453	0.00453	CcSEcCtD
Fosaprepitant—Stomatitis—Etoposide—muscle cancer	0.0045	0.0045	CcSEcCtD
Fosaprepitant—Malaise—Dactinomycin—muscle cancer	0.0045	0.0045	CcSEcCtD
Fosaprepitant—Mental disorder—Vincristine—muscle cancer	0.00448	0.00448	CcSEcCtD
Fosaprepitant—Urine output increased—Methotrexate—muscle cancer	0.00447	0.00447	CcSEcCtD
Fosaprepitant—Gait disturbance—Doxorubicin—muscle cancer	0.00439	0.00439	CcSEcCtD
Fosaprepitant—Hiccups—Doxorubicin—muscle cancer	0.00428	0.00428	CcSEcCtD
Fosaprepitant—Eructation—Doxorubicin—muscle cancer	0.00421	0.00421	CcSEcCtD
Fosaprepitant—Discomfort—Dactinomycin—muscle cancer	0.00419	0.00419	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Methotrexate—muscle cancer	0.00415	0.00415	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Etoposide—muscle cancer	0.00412	0.00412	CcSEcCtD
Fosaprepitant—Anaemia—Vincristine—muscle cancer	0.00412	0.00412	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Etoposide—muscle cancer	0.00409	0.00409	CcSEcCtD
Fosaprepitant—Candida infection—Doxorubicin—muscle cancer	0.00409	0.00409	CcSEcCtD
Fosaprepitant—Oedema—Dactinomycin—muscle cancer	0.00407	0.00407	CcSEcCtD
Fosaprepitant—Urethral disorder—Etoposide—muscle cancer	0.00406	0.00406	CcSEcCtD
Fosaprepitant—Infection—Dactinomycin—muscle cancer	0.00404	0.00404	CcSEcCtD
Fosaprepitant—Erythema multiforme—Etoposide—muscle cancer	0.00392	0.00392	CcSEcCtD
Fosaprepitant—Eye disorder—Etoposide—muscle cancer	0.00387	0.00387	CcSEcCtD
Fosaprepitant—Flushing—Etoposide—muscle cancer	0.00385	0.00385	CcSEcCtD
Fosaprepitant—Cardiac disorder—Etoposide—muscle cancer	0.00385	0.00385	CcSEcCtD
Fosaprepitant—Hypertension—Vincristine—muscle cancer	0.00385	0.00385	CcSEcCtD
Fosaprepitant—Angiopathy—Etoposide—muscle cancer	0.00376	0.00376	CcSEcCtD
Fosaprepitant—Immune system disorder—Etoposide—muscle cancer	0.00374	0.00374	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Etoposide—muscle cancer	0.00374	0.00374	CcSEcCtD
Fosaprepitant—Lethargy—Methotrexate—muscle cancer	0.00366	0.00366	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Vincristine—muscle cancer	0.00364	0.00364	CcSEcCtD
Fosaprepitant—Oedema—Vincristine—muscle cancer	0.00364	0.00364	CcSEcCtD
Fosaprepitant—Infection—Vincristine—muscle cancer	0.00361	0.00361	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Doxorubicin—muscle cancer	0.00359	0.00359	CcSEcCtD
Fosaprepitant—Osteoarthritis—Methotrexate—muscle cancer	0.00359	0.00359	CcSEcCtD
Fosaprepitant—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00357	0.00357	CcSEcCtD
Fosaprepitant—Nervous system disorder—Vincristine—muscle cancer	0.00357	0.00357	CcSEcCtD
Fosaprepitant—Decreased appetite—Dactinomycin—muscle cancer	0.00354	0.00354	CcSEcCtD
Fosaprepitant—Dysgeusia—Etoposide—muscle cancer	0.00353	0.00353	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Vincristine—muscle cancer	0.00351	0.00351	CcSEcCtD
Fosaprepitant—Fatigue—Dactinomycin—muscle cancer	0.00351	0.00351	CcSEcCtD
Fosaprepitant—Pain—Dactinomycin—muscle cancer	0.00348	0.00348	CcSEcCtD
Fosaprepitant—Muscle spasms—Etoposide—muscle cancer	0.00347	0.00347	CcSEcCtD
Fosaprepitant—Hypotension—Vincristine—muscle cancer	0.0034	0.0034	CcSEcCtD
Fosaprepitant—Feeling abnormal—Dactinomycin—muscle cancer	0.00335	0.00335	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Etoposide—muscle cancer	0.00335	0.00335	CcSEcCtD
Fosaprepitant—Anaemia—Etoposide—muscle cancer	0.00334	0.00334	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00333	0.00333	CcSEcCtD
Fosaprepitant—Hot flush—Doxorubicin—muscle cancer	0.00332	0.00332	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Doxorubicin—muscle cancer	0.00329	0.00329	CcSEcCtD
Fosaprepitant—Insomnia—Vincristine—muscle cancer	0.00329	0.00329	CcSEcCtD
Fosaprepitant—Malaise—Etoposide—muscle cancer	0.00325	0.00325	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00323	0.00323	CcSEcCtD
Fosaprepitant—Body temperature increased—Dactinomycin—muscle cancer	0.00322	0.00322	CcSEcCtD
Fosaprepitant—Abdominal pain—Dactinomycin—muscle cancer	0.00322	0.00322	CcSEcCtD
Fosaprepitant—Loss of consciousness—Etoposide—muscle cancer	0.00317	0.00317	CcSEcCtD
Fosaprepitant—Lethargy—Doxorubicin—muscle cancer	0.00317	0.00317	CcSEcCtD
Fosaprepitant—Decreased appetite—Vincristine—muscle cancer	0.00316	0.00316	CcSEcCtD
Fosaprepitant—Cough—Etoposide—muscle cancer	0.00315	0.00315	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Vincristine—muscle cancer	0.00314	0.00314	CcSEcCtD
Fosaprepitant—Fatigue—Vincristine—muscle cancer	0.00313	0.00313	CcSEcCtD
Fosaprepitant—Hyponatraemia—Doxorubicin—muscle cancer	0.00312	0.00312	CcSEcCtD
Fosaprepitant—Hypertension—Etoposide—muscle cancer	0.00312	0.00312	CcSEcCtD
Fosaprepitant—Constipation—Vincristine—muscle cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Pain—Vincristine—muscle cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Osteoarthritis—Doxorubicin—muscle cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Chest pain—Etoposide—muscle cancer	0.00307	0.00307	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00305	0.00305	CcSEcCtD
Fosaprepitant—Discomfort—Etoposide—muscle cancer	0.00304	0.00304	CcSEcCtD
Fosaprepitant—Hypersensitivity—Dactinomycin—muscle cancer	0.003	0.003	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—muscle cancer	0.00297	0.00297	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Vincristine—muscle cancer	0.00297	0.00297	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Etoposide—muscle cancer	0.00294	0.00294	CcSEcCtD
Fosaprepitant—Infection—Etoposide—muscle cancer	0.00293	0.00293	CcSEcCtD
Fosaprepitant—Asthenia—Dactinomycin—muscle cancer	0.00292	0.00292	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—muscle cancer	0.0029	0.0029	CcSEcCtD
Fosaprepitant—Body temperature increased—Vincristine—muscle cancer	0.00287	0.00287	CcSEcCtD
Fosaprepitant—Abdominal pain—Vincristine—muscle cancer	0.00287	0.00287	CcSEcCtD
Fosaprepitant—Skin disorder—Etoposide—muscle cancer	0.00286	0.00286	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Etoposide—muscle cancer	0.00285	0.00285	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Doxorubicin—muscle cancer	0.00284	0.00284	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—muscle cancer	0.00283	0.00283	CcSEcCtD
Fosaprepitant—Hypokalaemia—Doxorubicin—muscle cancer	0.00283	0.00283	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.0028	0.0028	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.0028	0.0028	CcSEcCtD
Fosaprepitant—Diarrhoea—Dactinomycin—muscle cancer	0.00278	0.00278	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—muscle cancer	0.00277	0.00277	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—muscle cancer	0.00277	0.00277	CcSEcCtD
Fosaprepitant—Hypotension—Etoposide—muscle cancer	0.00275	0.00275	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00274	0.00274	CcSEcCtD
Fosaprepitant—Muscular weakness—Doxorubicin—muscle cancer	0.00274	0.00274	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00274	0.00274	CcSEcCtD
Fosaprepitant—Abdominal distension—Doxorubicin—muscle cancer	0.0027	0.0027	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—muscle cancer	0.0027	0.0027	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—muscle cancer	0.00269	0.00269	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vincristine—muscle cancer	0.00268	0.00268	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—muscle cancer	0.00264	0.00264	CcSEcCtD
Fosaprepitant—Dyspnoea—Etoposide—muscle cancer	0.00263	0.00263	CcSEcCtD
Fosaprepitant—Somnolence—Etoposide—muscle cancer	0.00262	0.00262	CcSEcCtD
Fosaprepitant—Asthenia—Vincristine—muscle cancer	0.00261	0.00261	CcSEcCtD
Fosaprepitant—Vomiting—Dactinomycin—muscle cancer	0.00259	0.00259	CcSEcCtD
Fosaprepitant—Rash—Dactinomycin—muscle cancer	0.00257	0.00257	CcSEcCtD
Fosaprepitant—Decreased appetite—Etoposide—muscle cancer	0.00256	0.00256	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Etoposide—muscle cancer	0.00254	0.00254	CcSEcCtD
Fosaprepitant—Fatigue—Etoposide—muscle cancer	0.00254	0.00254	CcSEcCtD
Fosaprepitant—Constipation—Etoposide—muscle cancer	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Pain—Etoposide—muscle cancer	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—muscle cancer	0.00251	0.00251	CcSEcCtD
Fosaprepitant—Diarrhoea—Vincristine—muscle cancer	0.00249	0.00249	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—muscle cancer	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—muscle cancer	0.00245	0.00245	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—muscle cancer	0.00245	0.00245	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—muscle cancer	0.00243	0.00243	CcSEcCtD
Fosaprepitant—Weight decreased—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Fosaprepitant—Feeling abnormal—Etoposide—muscle cancer	0.00243	0.00243	CcSEcCtD
Fosaprepitant—Nausea—Dactinomycin—muscle cancer	0.00242	0.00242	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Etoposide—muscle cancer	0.00241	0.00241	CcSEcCtD
Fosaprepitant—Dizziness—Vincristine—muscle cancer	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—muscle cancer	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Urticaria—Etoposide—muscle cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Body temperature increased—Etoposide—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Abdominal pain—Etoposide—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—muscle cancer	0.00232	0.00232	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—muscle cancer	0.00231	0.00231	CcSEcCtD
Fosaprepitant—Vomiting—Vincristine—muscle cancer	0.00231	0.00231	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—muscle cancer	0.0023	0.0023	CcSEcCtD
Fosaprepitant—Rash—Vincristine—muscle cancer	0.00229	0.00229	CcSEcCtD
Fosaprepitant—Dermatitis—Vincristine—muscle cancer	0.00229	0.00229	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Fosaprepitant—Headache—Vincristine—muscle cancer	0.00228	0.00228	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—muscle cancer	0.00225	0.00225	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—muscle cancer	0.00224	0.00224	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—muscle cancer	0.00224	0.00224	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Hypersensitivity—Etoposide—muscle cancer	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Fosaprepitant—Nausea—Vincristine—muscle cancer	0.00216	0.00216	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—muscle cancer	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—muscle cancer	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—muscle cancer	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Asthenia—Etoposide—muscle cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—muscle cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—muscle cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Pruritus—Etoposide—muscle cancer	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Diarrhoea—Etoposide—muscle cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—muscle cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—muscle cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—muscle cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—muscle cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—muscle cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—muscle cancer	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—muscle cancer	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Dizziness—Etoposide—muscle cancer	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—muscle cancer	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—muscle cancer	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—muscle cancer	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Fosaprepitant—Vomiting—Etoposide—muscle cancer	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Rash—Etoposide—muscle cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Dermatitis—Etoposide—muscle cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Headache—Etoposide—muscle cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—muscle cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—muscle cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—muscle cancer	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—muscle cancer	0.0018	0.0018	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Nausea—Etoposide—muscle cancer	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—muscle cancer	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—muscle cancer	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—muscle cancer	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—muscle cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—muscle cancer	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—muscle cancer	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—muscle cancer	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—muscle cancer	0.00157	0.00157	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—muscle cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—muscle cancer	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—muscle cancer	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—muscle cancer	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—muscle cancer	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—muscle cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—muscle cancer	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—muscle cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—muscle cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—muscle cancer	0.00138	0.00138	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—muscle cancer	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—muscle cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—muscle cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—muscle cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—muscle cancer	0.00127	0.00127	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—muscle cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—muscle cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—muscle cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—muscle cancer	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—muscle cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—muscle cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—muscle cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—muscle cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—muscle cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—muscle cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—muscle cancer	0.00108	0.00108	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—muscle cancer	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—muscle cancer	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Dizziness—Doxorubicin—muscle cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—muscle cancer	0.000971	0.000971	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—muscle cancer	0.000963	0.000963	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—muscle cancer	0.000962	0.000962	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—muscle cancer	0.000957	0.000957	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—muscle cancer	0.000907	0.000907	CcSEcCtD
